ARTICLE | Clinical News
Galeterone: Phase II discontinued
September 5, 2016 7:00 AM UTC
Tokai discontinued enrollment in the expansion portion of the open-label, international Phase II ARMOR2 trial of once-daily oral galeterone for 3 months in patients with acquired Xtandi enzalutamide ...